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Objective: To assess whether passive smoking
exposure at home is a risk factor for community-
acquired pneumonia (CAP) in adults.
Setting: A population-based case-control study was
designed in a Mediterranean area with 860 000
inhabitants >14 years of age.
Participants: 1003 participants who had never
smoked were recruited.
Primary and secondary outcome measures: Risk
factors for CAP, including home exposure to passive
smoking, were registered. All new cases of CAP in a
well-defined population were consecutively recruited
during a 12-month period.
Methods: A population-based case-control study was
designed to assess risk factors for CAP, including
home exposure to passive smoking. All new cases of
CAP in a well-defined population were consecutively
recruited during a 12-month period. The subgroup of
never smokers was selected for the present analysis.
Results: The study sample included 471 patients with
CAP and 532 controls who had never smoked. The
annual incidence of CAP was estimated to be 1.14
cases×10–3 inhabitants in passive smokers and
0.90×10−3 in non-passive smokers (risk ratio (RR)
1.26; 95% CI 1.02 to 1.55) in the whole sample. In
participants ≥65 years of age, this incidence was
2.50×10−3 in passive smokers and 1.69×10−3 in non-
passive smokers (RR 1.48, 95% CI 1.08 to 2.03). In
this last age group, the percentage of passive smokers
in cases and controls was 26% and 18.1%,
respectively (p=0.039), with a crude OR of 1.59 (95%
CI 1.02 to 2.38) and an adjusted (by age and sex) OR
of 1.56 (95% CI 1.00 to 2.45).
Conclusions: Passive smoking at home is a risk
factor for CAP in older adults (65 years or more).
INTRODUCTION
Community-acquired pneumonia (CAP) is an
important cause of morbidity and mortality in
industrialised countries. In the general adult
population, the annual incidence of CAP
ranges between 1.6 and 13.4 cases/1000 inhabi-
tants, with a need for inpatient care between
22% and 51%, and a lethality of 3–24%,1–3
which remained unchanged in recent years
despite the use of preventive measures.4 There
is strong evidence of an association between
active tobacco smoking and the risk for CAP.5–8
Tobacco has a direct and independent effect
on the risk for CAP and may act indirectly
causing chronic bronchitis or chronic obstruct-
ive pulmonary disease (COPD), which in turn
are well-recognised risk factors for CAP.8
Therefore, one of the main actions for prevent-
ing CAP is a smoking cessation intervention.
There has also been an increasing interest
to assess the effects of passive smoking.
Although some studies suggested that passive
smoking may be associated with a higher risk
of respiratory infections in children whose
parents smoke9–11 and adults,12 13 the effect of
exposure to passive smoking on CAP is still
unclear. In most developed countries, expos-
ure to tobacco smoke has been reduced by
Strengths and limitations of this study
▪ The effect of passive smoking at home on
community-acquired pneumonia in adults is
controversial.
▪ The present findings add new evidence of the
unfavourable effect of exposure to passive
smoking at home based on data from a large
population-based study.
▪ It shows a significant effect only in participants
aged 65 years or older.
▪ Passive smoking was assessed by a self-reported
questionnaire which could lead to an imprecise
exposure quantitative measure.
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approximately 20–25% due to smoking bans, which pro-
hibit tobacco smoking in workplaces and outdoor public
areas.13 However, tobacco laws prohibiting smoking in
workplaces and leisure spaces do not have any influence
on tobacco consumption in the home environment. This
study was aimed to assess the influence of passive smoking
exposure at home on the occurrence of CAP in adults.
PATIENTS AND METHODS
A population-based case–control study designed to identify
risk factors for CAP (Community-acquired pneumonia in
Health Care Centres; PACAP study) was conducted in an
extensive rural and urban area on the eastern coast of
Spain, with predominantly Mediterranean climatic condi-
tions. Details of the study have been previously published.14
An initial prospective phase allowed identification of all
new cases of CAP diagnosed during a 1-year period and to
estimate the incidence of CAP in the target population,
which included 859 033 inhabitants older than 14 years
assigned to any of the 64 participating primary care
centres. Control participants were frequency matched by
age (±5 years), sex and primary healthcare area with cases.
Controls were selected at random from the databases of
the primary care centres. For the identification of cases, an
active and exhaustive search of all cases of clinically sus-
pected CAP presented over a 1-year period was conducted.
To this purpose, an active surveillance system was estab-
lished to ensure the identification of all cases of CAP diag-
nosed in public and private healthcare facilities in the
study area. Predefined criteria for case registration were
acute lower respiratory tract infection for which antibiotics
had been prescribed, in association with the appearance of
new or previously unknown focal signs on physical examin-
ation and radiography of the chest. All cases of CAP were
periodically re-evaluated by chest radiography at monthly
intervals until complete recovery. Patients with suspicion of
CAP in whom another non-infectious respiratory disease
was later confirmed were excluded from the study, as were
patients with active tuberculosis, aspiration pneumonia and
healthcare-associated pneumonia. Cases of CAP were fol-
lowed up for 4 weeks or until complete recovery. A ques-
tionnaire on CAP risk factors was administered to cases and
controls at home. When the participant could not directly
answer the questions (cognitive impairment, disease or, for
CAP cases, death), the questionnaire was administered to
the closest family member or caregiver. The interviewers
were physicians or nurses trained in interview techniques
and in the administration of the study questionnaire. The
instrument was structured into three sections related to the
following aspects: (1) health habits and lifestyle; (2)
chronic respiratory diseases and other clinical conditions;
and (3) regular treatments during the past year. History of
tobacco use, and passive smoking at work and at home
were also recorded. Passive tobacco consumption was
assessed by the question: ‘Do you currently live with one or
more smokers at home?’ with two (yes/no) possible
answers. All participants gave written informed consent.
Data analysis
For the purpose of this analysis, only cases and controls who
never smoked were selected. Participants were further classi-
fied into passive smokers at home and non-passive smokers
at home. The effect of passive smoking exposure at home
on CAP was assessed by two strategies: (1) estimation of the
annual incidence of CAP in passive and non-passive
smokers and calculation of the relative risk (RR) and its
95% CI using data from the prospective phase of the study;
and (2) estimation of the OR and its 95% CI by logistic
regression analysis using data from the case–control study.
To estimate the incidence of CAP in participants exposed
and non-exposed to passive smoking, it was assumed that
the proportion of passive and non-passive smokers at home
in each age and sex group of the study population was the
same as that observed in the control group sample, consid-
ered highly representative of the study population because
of its random selection from primary care databases and
with a 99.3% of population coverage.15 In the control
group (n=1326), overall prevalence of never smokers was
48.5% and the prevalence of passive smokers at home was
10.6% (or 26.3% of never smokers). These data were strati-
fied by age and sex groups and applied to the general popu-
lation distribution (Catalan Statistics Institute, http://www.
idescat.cat) to determine the denominators (total popula-
tion at risk) in the estimation of the CAP incidence.
Moreover, the attributable risk (AR; exposed risk−non-
exposed risk) and the aetiological fraction (AF) in exposed
population (AF%; (exposed risk−non-exposed risk)×100/
exposed risk) were estimated as impact measures of passive
smoking. In the case-control study, OR was adjusted by age
and sex since, in this analysis matching was broken when
selecting only never smokers. Also, all analyses were made
for the overall study population and stratifying by <65 and
≥65 years of age. The Statistical Package for the Social
Sciences (SPSS, V.15) was used for the analysis of data.
Statistical significance was set at p<0.05, or in the RR and
OR estimations if the 95% CI did not include 1.0.
RESULTS
A total of 1003 participants who never smoked were
selected from the PACAP database study, 283 (28.2%) of
whom reported to be in contact with tobacco smoke at
home and were classified as passive smokers at home.
Among these cases, 75% were women (median age:
65 years, range 14–96), whereas 71% of controls were
women (median age: 63 years, range 15–100).
Standardised prevalence of passive smoking at home in
the study population was estimated at 28.4%. A compari-
son of the percentage of passive smokers between cases
and controls did not show statistically significant differ-
ences either in the overall study sample (30.4% vs 26.3%,
p=0.155) or in the subset of participants younger than
65 years (46.1% vs 33.8%, p=0.931). However, in partici-
pants aged 65 years or older, the percentage of passive
smokers was significantly higher in cases with CAP than in
controls (26% vs 18.1%, p=0.039). Table 1 shows the effect
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(OR) of passive smoking on CAP for the overall study
sample and for the age subgroups, with a significant effect
only in participants aged 65 years or more, with an OR
that remained almost invariable after adjusting by age and
sex. In the study sample, passive smoking exposure at
home was not associated with other known risk factors for
CAP, such as chronic bronchitis, COPD, upper respiratory
tract infection in the previous month, hospital admission
in the previous 5 years, history of any previously confirmed
pneumonia, sudden changes of temperature in the work-
place in the previous 3 months, so that passive tobacco
consumption was not adjusted by these variables.
The annual incidence of CAP in participants exposed
and non-exposed to passive smoking in the home environ-
ment, RR, AR and AF for the overall study sample and for
subgroups of age is summarised in table 2. A statistically
significant effect of passive tobacco exposure was observed
in participants aged 65 years or older; in whom passive
smoking carried a 48% increase in the risk for CAP.
DISCUSSION
The results of the present analysis show that age modifies
the effect of passive smoking on CAP. Participants aged
65years or older passive smokers are at a higher risk for
CAP than non-exposed participants with an OR of 1.59,
while this effect disappeared in participants under
65 years of age. There is abundant scientific evidence of
the effect of tobacco on CAP but evidence of the effect of
passive smoking is scarcer. It is well known that smoking is
one of the main independent risk factors for CAP and
determines its severity.7 16–18 This risk is directly associated
with the number of cigarettes smoked and it reduces after
quitting.8 Probably this may be explained by structural pul-
monary lesions and alterations of the immune response—
innate and adaptative—as a result of smoking19 20 which
may favour the presence and propagation of microorgan-
isms in the bronchial tree. Also, tobacco consumption
increases tissue oxidative stress especially in the lung pro-
voking lesions in the respiratory epithelium, connective
tissue and vascular endothelium, which may increase their
sensitivity to the inflammatory aggression of the infec-
tion,19–21 even at low concentrations of smoke.22 Owing to
these profound mechanisms, tobacco smoke may be an
important risk factor for CAP also in passive smokers.9 10
The effect of passive smoking on the risk of CAP has
been previously reported in patients older than 65 years
requiring inpatient care for CAP12 and in patients
between 18 and 64 years of age with pneumococcal bac-
teraemia.11 However, the influence of passive smoking
exposure on the appearance of CAP in adults of all ages
on the basis of a population-based study was not well
known and uncertain. Nuorti et al11 showed that
smoking was the main independent risk factor for inva-
sive pneumococcal disease in immunocompetent adults
aged between 18 and 64 years, with an OR of 4.1 in
active smokers and 2.5 in passive smokers. In the present
study, exposure to passive smoking in the home environ-
ment only showed an effect in participants 65 years or
over, in whom a 59% risk excess was observed. Age
seems to modify the effect of passive smoking on CAP
but it is not clear if this interaction is due to age ‘per se’
or if it is due to prolonged exposure or a different or
more intense exposure pattern to passive tobacco smoke
at home in elderly participants. Moreover, in older
persons the defence mechanisms may be more impaired
and outweighed by this aggression. By contrast, in
Table 1 Effect of passive tobacco consumption at home
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younger participants, specific and non-specific defence
mechanisms may counterbalance the aggression of
tobacco smoke caused by other smokers.
The prevalence of passive smokers at home observed in
the present study is very similar to that previously published
regarding the Spanish population in 2005 (29.5%), prior to
the smoking ban coming into force,23 which reinforces the
reliability of the present data. This prevalence indicates the
magnitude of exposure to a factor which has a remarkable
impact on the risk of CAP. Thus, approximately one-third of
pneumonic episodes in passive smokers >65 years of age are
due to exposure to tobacco smoke from other persons at
home and could be avoided if this factor was eliminated.
The present findings, together with evidence of the effect-
iveness of the pneumococcal vaccine,24 25 in particular, the
conjugate vaccine,26 suggest that vaccination could be admi-
nistered to active smokers and participants older than
65 years of age who cannot avoid being exposed to passive
smoking in the household environment. The main study
limitations include inaccuracy of quantitatively measured
passive tobacco smoke exposure since exposure intensity
was not considered and coinhabitats who smoke at home
may go to smoke outside. However, this circumstance was
the same for cases and controls and, although it may have
diluted the expected effect, a bias was not introduced. We
have not taken into account passive exposure at work or in
public places, which is now forbidden but was allowed when
the study was conducted, because our aim was focused on
the effect of passive smoking at home.
In summary, the present study adds new evidence of the
effect of passive smoking on CAP in adults from a
population-based study. It shows a significant effect only in
participants 65 years old or above, who may be exposed
for a prolonged period of time, with a more intensive
pattern of exposure and whose pulmonary defence
mechanisms may be impaired or debilitated. These results
must be taken into account when considering preventive
measures for CAP in this specific age population, such as
changes in lifestyle factors or vaccination.
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